Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) announced its participation at the 2023 American Academy of Neurology (AAN) Annual Meeting, showcasing its XEN1101 epilepsy program. An oral presentation by Dr. Jacqueline French will detail interim results from the open-label extension of the Phase 2b X-TOLE study, highlighting a sustained monthly seizure frequency reduction of 80%-90% from baseline and seizure freedom in 17.5% and 10.5% of patients for ≥6 and ≥12 months, respectively. Additionally, Xenon will present its Phase 3 study, X-ACKT, which evaluates XEN1101 in primary generalized tonic-clonic seizures, aiming for regulatory submissions. The trial will assess the drug's safety and efficacy in approximately 160 patients.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical firm, will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto from April 25-26, 2023. The company's presentation is scheduled for April 25, 2023, at 11:00 am Eastern Time (8:00 am Pacific Time). Investors can register for a live webcast of the event here. Ian Mortimer, the President and CEO, will be the presenter. A replay of the webcast will be available on the company's website post-event. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The company will participate in a fireside chat on April 20, 2023, at 2:15 PM ET (11:15 AM PT). Company executives Ian Mortimer (President and CEO) and Sherry Aulin (CFO) will present. Investors can access a live webcast of the presentation on Xenon's website, with a replay available post-event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly in epilepsy, with a commitment to addressing unmet medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company focused on neurology, will present at the virtual Stifel 2023 CNS Days on March 28-29, 2023. The presentation will feature Ian Mortimer, President and CEO, and Sherry Aulin, CFO, on March 28 at 1:00 PM Eastern Time (10:00 AM Pacific Time). A live webcast will be available and can be pre-registered for via a provided link. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly epilepsy. For further information, visit www.xenon-pharma.com.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
